Top Stories
The new collaboration will utilise CSPC's siRNA drug discovery platform and extrahepatic targeted delivery platform to develop small nucleic acid drug candidates for renal diseases across multiple indications.
While Insilico will lead initial discovery and design efforts, Takeda will assume further development responsibilities for selected candidates.
Merck & Co. ended a Phase II Alzheimer's disease dementia study, while Angitia terminated a Phase III trial in patients with degenerative disc disease.
BBP-418, an experimental therapy for limb-girdle muscular dystrophy type 2I/R9, is expecting an FDA decision by its Nov. 27 deadline.
The company's lead candidate is designed to treat hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.
Conference News
Abstract recently submitted in anticipation of initial data analysis ahead of ESCCompany expects to report topline LEVEL results in AugustCHAPEL HILL, N.C., July 02, 2026 (GLOBE NEWSWIRE) -- Tenax The...
The place for TACE combos in eeHCC is still uncertain ...
Zoldonrasib combinations show encouraging response rates in KRAS G12D-mutant pancreatic cancer2 Jul 2026Pancreatic Adenocarcinoma ESMO Gastrointestinal Cancers Congress 2026Positive findings are repor...
New Taipei City, Taiwan, July 02, 2026 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (Nasdaq: MENS) (the “Company” or “Jyong Biotech”), a science-driven biotechnology company dedicated to the development and...
REDWOOD CITY, Calif., July 02, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted c...
